ArticleAmerican journal of human genetics2026
Identification of de novo variants from parent-proband duos via long-read sequencing.
Article in American journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EstimatingbioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
While de novo variants cause many Mendelian disorders, their detection currently requires sequencing of the proband and both biological parents. This is not feasible when only one parent is available, a limitation for millions of families. Here, we develop duoNovo, which identifies de novo variants from parent-proband duos using long-read sequencing followed by haplotype reconstruction and detection of identical-by-descent haplotype blocks. We sequenced 104 trios with PacBio HiFi sequencing and applied duoNovo to each of the 208 duos constructed by masking one parent, classifying over 55 million variants according to their de novo status. We evaluated duoNovo's performance against classifications obtained using the full trios (which included over 10,000 de novo variants), finding a positive predictive value of ∼98% among variants absent from gnomAD and a sensitivity of approximately 55% from father-proband duos (73% of the biological upper limit) and 14% from mother-proband duos (56% of the biological upper limit), the latter increasing to ∼24% when a sibling is available. In a cohort of 63 undiagnosed duos, duoNovo provided critical diagnostic information for two probands. In summary, duoNovo has the potential to significantly increase the diagnostic yield of single-parent genetic testing and represents an example where long-read sequencing provides a clear benefit over short-read sequencing even for single-nucleotide variants. It is freely available as an R package.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.